Biogen Inc.

Biogen Inc. is a leading multinational biotechnology company headquartered in Cambridge, Massachusetts, that specializes in discovering and delivering therapies for neurological and neurodegenerative diseases. Founded in 1978, the company has pioneered breakthroughs for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease with a product portfolio including Tecfidera, Tysabri, and Spinraza. Beyond its core neuroscience focus, Biogen has expanded its expertise into immunology and rare diseases, further bolstered by its 2026 acquisition of Apellis Pharmaceuticals. With a global workforce and significant manufacturing operations in North Carolina, the organization remains dedicated to advancing innovative science to transform patient lives worldwide.